All data are based on the daily closing price as of December 5, 2024
d
Dong-A ST
170900.KO
42.72 USD
-0.11
-0.26%
Overview
Last close
42.72 usd
Market cap
383.95M usd
52 week high
64.42 usd
52 week low
39.59 usd
Target price
64.96 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
0.8064
Price/Book Value
0.8427
Enterprise Value
503.84M usd
EV/Revenue
1.0189
EV/EBITDA
48.9549
Key financials
Revenue TTM
476.90M usd
Gross Profit TTM
205.36M usd
EBITDA TTM
7.05M usd
Earnings per Share
N/A usd
Dividend
0.49 usd
Total assets
1,429.76B usd
Net debt
N/A usd
About
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Dulastin PFS and Leucostim injection/PFS to treat neutropenia in patients receiving myelosuppressive chemotherapy; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation; Growtropin II inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Mainta inj. for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel inj. to treat breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone tab. for use in functional dyspepsia treatment; Stillen tab. to treat gastritis; Suganon tab./Sugamet XR tab. for type 2 diabetes mellitus; Terizidone tab to treat active pulmonary and extra-pulmonary tuberculosis; and Zydena tab. for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high-technology medical devices, custom-made products, and sets of artificial cardiac circuits for use in open-heart surgery. Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.